G Shellye Horowitz

3 weeks ago | hemophilianewstoday.com | Andrea Lobo |Patricia Inacio |Alliah Czarielle |G Shellye Horowitz

Despite high rates of bone health issues in hemophilia and von Willebrand disease (VWD), the routine use of DEXA scans remains low across hemophilia treatment centers (HTCs) in the U.S., a study reports. DEXA, or dual-energy X-ray absorptiometry, is a type of imaging test that uses low-dose X-rays to measure bone density and check for osteoporosis, which is where bones become weaker and more likely to break.

1 month ago | hemophilianewstoday.com | Marisa Wexler |Lindsey Shapiro |G Shellye Horowitz |Alliah Czarielle

The Loma Linda University Health (LLUH) Hemophilia Treatment Center has become the first clinic in California offering Hympavzi (marstacimab) for people with hemophilia B. “For the first time, patients with hemophilia B in Southern California have access to a therapy that is not just effective, but also drastically improves their daily lives,” Akshat Jain, MD, director of the Hemophilia Treatment Center at LLUH, said in a news story from the clinic.

2 months ago | hemophilianewstoday.com | Alliah Czarielle |G Shellye Horowitz |Joe MacDonald

When people talk about hemophilia, some deliberately avoid calling it a disability. Instead, they’ll say “a medical condition” or “a health challenge,” as if disability were a negative label. Some who embrace the positive thinking movement even argue that people with hemophilia shouldn’t see it as a disability, pushing the idea that they should overcome their limitations at all costs.

2 months ago | hemophilianewstoday.com | Jennifer Lynne |G Shellye Horowitz

Women like me often wonder how the hemophilia community has overlooked us for so long. The stories of women labeled as mere “carriers” — despite experiencing life-threatening bleeding episodes — are endless. For decades, we’ve lived with symptoms that disrupt our lives, yet we were dismissed, misdiagnosed, or told we couldn’t possibly have hemophilia. I recently had a light bulb moment while listening to “Unmuted,” a Hope for Hemophilia podcast.

Nov 15, 2024 | hemophilianewstoday.com | Andrea Lobo |Margarida Maia |Jennifer Lynne |G Shellye Horowitz

Centessa Pharmaceuticals is discontinuing the clinical development of SerpinPC, its experimental under-the-skin therapy for people with hemophilia A and hemophilia B with or without inhibitors. The therapy was being evaluated in several Phase 2 clinical trials. The decision follows the recent approval of Pfizer’s Hympavzi (marstacimab), an antibody-based treatment that’s designed to increase the production of thrombin, a protein that promotes blood clotting, in a mechanism similar to SerpinPC’s.